Urine Alkalinisation to Prevent AKI in COVID-19 | NCT04655716 | Trialant

Urine Alkalinisation to Prevent AKI in COVID-19 | NCT04655716 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Sodium bicarbonate	Experimental	Intravenous sodium bicarbonate infusion	Drug: Sodium Bicarbonate 150Meq/L/D5W Inj
Standard care	No Intervention	Standard of care by the clinical team

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Sodium Bicarbonate 150Meq/L/D5W Inj	Drug	Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
proportion of patients treated who achieve >50% of urine measurements above pH 7.0 over the duration of intervention	proportion of patients treated who achieve >50% of urine measurements above pH 7.0 over the duration of intervention	up to 10 days after intensive care unit admission

Secondary Outcomes

Measure	Description	Time Frame
number of days alive and free of stage 2-3 AKI (up to day 28) in each group	number of days alive and free of stage 2-3 AKI (up to day 28) in each group	up to day 28 after randomisation
proportion of patients developing stage 2-3 AKI

Contacts/Locations Module

Condition Browse Module